BioMedNewsBreaks — Diagnos Inc. (TSX Venture: ADK) (OTCQB: DGNOF) (FWB: 4D4A) Engages IBN for Corporate Communications and Awareness

Disseminated on behalf of Diagnos Inc. and may include paid advertising. 

Diagnos (TSX Venture: ADK) (OTCQB: DGNOF) (FWB: 4D4A), a pioneer in early detection of critical health issues using Artificial Intelligence-based technology, announced it has engaged Investor Brand Network (“IBN”) to provide corporate communication and awareness solutions. Under the one-year agreement effective Jan. 10, 2026, IBN will receive monthly compensation of US$6,400, payable in advance in cash from the Corporation’s funds. IBN will assist Diagnos in refining and strengthening its market awareness profile with the objective of maximizing shareholder value, is acting at arm’s length, and, together with its principals, holds no direct or indirect interest in the Corporation’s securities. The engagement remains subject to acceptance by the TSX Venture Exchange.

To view the full press release, visit https://ibn.fm/iuKnO

About Diagnos

Diagnos is a publicly traded Canadian corporation dedicated to early detection of critical eye-related health problems. By leveraging Artificial Intelligence, DIAGNOS aims to provide more information to healthcare clinicians to enhance diagnostic accuracy, streamline workflows, and improve patient outcomes on a global scale.

Additional information is available at www.diagnos.com and www.sedarplus.com.

NOTE TO INVESTORS: The latest news and updates relating to DGNOF are available in the company’s newsroom at https://ibn.fm/DGNOF

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN